Skip to content

Text Size: AAA

Investors

Printer Friendly Version Print  |  E-mail this page Email  |  E-mail Alerts Alerts  |  RSS RSS  |  View contacts Contacts  |  Download Financial Tear Sheet Tear Sheet

Webcast ImageWebcast
Amylin Pharmaceuticals, Inc. at Leerink Swann Global Healthcare Conference (Replay)
02/16/12 at 2:00 p.m. ET
Our Investor Relations Center is provided to give you convenient access to company information, including financial reports, press releases and corporate events. You can also sign up to be reminded via email of any upcoming company presentations, or to be notified of news releases and other announcements.

If you cannot find the information you're looking for on our website please let us know, and we will do our best to accommodate your request.
Featured Report
Download Documentation 2010 Annual Report
RECEIVE E-MAIL ALERTS
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
Stock Quote
AMLN (Common)
ExchangeNASDAQ (US Dollar)
Price$17.46
Change (%) Stock is Up 0.30 (1.75%)
Volume1,666,032
Data as of 02/22/12 1:16 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore
DateTitle 
02/17/12CHMP Recommends Approval of BYETTA® for Use With Basal Insulin
Patients in Pivotal Study Achieved Better Glycemic Control Without Weight Gain or Increased Hypoglycemia Risk Versus Optimized Insulin Glargine SAN DIEGO and INDIANAPOLIS, Feb. 17, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion in the European Union (EU) for the expanded use of BYETTA®... 
Printer Friendly Version
02/13/12BYDUREON™, First and Only Once-Weekly Type 2 Diabetes Treatment, Now Available in U.S. Pharmacies
BYDUREON Steady Support(SM) Available to Help Patients Successfully Start and Maintain Therapy SAN DIEGO and DUBLIN, Feb. 13, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that BYDUREON™ (exenatide extended-release for injectable suspension) is now available by prescription in U.S. pharmacies. The U.S. Food and Drug Administration (FDA) approved BYDUREON, the first and only once-weekly treatment for type 2 ... 
Printer Friendly Version
02/09/12Amylin Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Leerink Swann 2012 Global Healthcare Conference in New York on Thursday, February 16, 2012 at 2:00 p.m. ET / 11:00 a.m. PT. Mark Foletta, senior vice president, finance and chief financial officer at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com, and a record... 
Printer Friendly Version
02/06/12Amylin Pharmaceuticals Reports Fourth Quarter and Full Year 2011 Financial Results
Strategic Execution, Fiscal Discipline in 2011 Yield Non-GAAP Operating Income of $26 Million SAN DIEGO, Feb. 6, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2011. Total revenue for the quarter ended December 31, 2011 was $164.9 million, which included net product sales of $160.9 million. Non-GAAP operating income for the quarter ended December 31, 2011 was $17.6 million, compared to a non-GA... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.